Trials / Completed
CompletedNCT02776137
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck，A Non-Randomized Phase II Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase II, open label study of postoperative concurrent chemoradiotherapy with docetaxel for high-risk squamous cell carcinoma of the head and neck(HNSCC).The primary purpose of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy with docetaxel in HNSCC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel: 20mg/m2/w for 6 weeks |
| RADIATION | Intensity-modulated radiotherapy | a total dose of 60Gy in 30 fractions over 6 weeks |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-12-01
- Completion
- 2019-02-01
- First posted
- 2016-05-18
- Last updated
- 2020-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02776137. Inclusion in this directory is not an endorsement.